Androgenetic Alopecia Clinical Trial
— CS-SAGA-001Official title:
A Randomised, Evaluator-Blinded, Two-Arm Study To Evaluate The Safety And Efficacy of a Novel Microneedle and Laser-Based Medical Device For The Treatment of Androgenetic Alopecia in Adult Males
Verified date | August 2023 |
Source | StimuSIL |
Contact | Ana I Villalba |
Phone | +34 647160346 |
ana[@]stimusil.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this 24-week study is to see if the SAGA-001 device is safe and effective at helping people with male pattern hair loss. Two different device configurations are being explored as part of this study. Device A has novel microneedles, lasers, and additional metal microneedles, while Device B only has novel microneedles and lasers. Participants will receive 12 treatments with either Device A or Device B over the course of 24 weeks. Treatments will be performed on-site every two weeks.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | September 1, 2024 |
Est. primary completion date | May 1, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 22 Years to 55 Years |
Eligibility | Inclusion Criteria: - Subject is willing to sign an informed consent form - Subject is within the age group of 22-55 years (including both ages) - Subject is male - Subject has AGA with a Stage IIa-V Hamilton-Norwood classification - Subject's skin is within Fitzpatrick Skin Types I-IV Exclusion Criteria: - Subjects who have used any formulation or application/administration or type of treatment for disorders of the skin or scalp within 180 days prior to screening, including but not limited to the following treatments: 1. Anti-inflammatory medications, including topical steroids 2. Antifungal 3. Skin, nail, hair rejuvenation supplementation, or IV infusions (includes vitamin, minerals, herbals, etc.) 4. Hair growth shampoos, conditioners, and topicals 5. Topical, dermal or oral minoxidil, finasteride, or dutasteride 6. Hair growth stimulation treatments, i.e. PRP, stem cells, exosomes, growth factors, microneedling, mesotherapy 7. LED or low level laser therapy treatments, ie. laser helmets, laser caps, and laser combs 8. Infrared saunas - Subjects with alopecia other than AGA, such as alopecia areata, alopecia totalis, telogen effluvium, anagen effluvium, and acquired cicatricial alopecia - Subjects with a history of bleeding disorders - Subjects on anticoagulant medications (aspirin, warfarin, heparin) - Subject on autoimmune suppressant medications or suffering autoimmune diseases (e.g. humira) - Subjects with an active infection at the local site - Subjects with keloidal tendencies - Subjects with chronic dermatological conditions affecting the scalp (e.g. eczema, psoriasis, etc.) - Subjects with hepatic or renal disease, epilepsy, or any other major medical illness* - Subjects that have undergone evaluation to rule out other causes of hair loss, because underlying causes (e.g., iron deficiency, lupus, thyroid disease, telogen effluvium, post-pregnancy, polycystic ovary, chemotherapy, etc.) would preclude assessment of performance in an androgenetic alopecia trial - Subjects who are photosensitive or are using photosensitive drugs or topicals. - Subjects who are taking anxiolytics medications - Subjects who have been on hormone inhibitors or on hormone replacement therapy in the last 180 days - Subjects who are at high risk of seizures - Subjects who have a malignancy or a history of malignancies affecting the scalp - Subjects that have undergone hair transplantation, scalp reduction, radiation to the scalp or chemotherapy within their lifetime. - Subjects with current hair weaves, hair extensions, scalp tattoos, or who use occlusive wigs. - Subjects who have used semi-permanent hair products (e.g. color, texturizers or relaxers) within 30 days prior to screening. - Subjects with hair shorter than one-half inch (approximately 1.2 cm). - Subjects who are unable to make regular follow-up visits. - Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative sites, or individuals who are directly affiliated with the study at the investigative sites, or individuals directly affiliated with the study sponsor. |
Country | Name | City | State |
---|---|---|---|
Turkey | Ankara Bilkent Sehir Hastanesi Dermatoloji Klini | Ankara | |
Turkey | Istanbul Üniversitesi Cerrahpasa Tip Fakültesi, Dahili Tip Bilimleri Bölümü Deri ve Zührevi Hastaliklar Ana Bilim Dali Kocamustafa Pasa | Istanbul |
Lead Sponsor | Collaborator |
---|---|
StimuSIL | Ankara City Hospital Bilkent, Istanbul University - Cerrahpasa (IUC) |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in terminal hair density | Changes in terminal hair density at the 24-week time point compared to baseline will be investigated using a binomial test for one proportion at a one-sided alpha with a 95% exact confidence interval, considering pi = 60%, where pi is the true percentage of responders in the study population. | 24 weeks | |
Primary | Change in terminal hair density | Changes in terminal hair density at the 16-week time point compared to baseline will be investigated using a binomial test for one proportion at a one-sided alpha with a 95% exact confidence interval, considering pi = 60%, where pi is the true percentage of responders in the study population. | 16 weeks | |
Secondary | Change in hair thickness | Increases and/or decreases in hair diameter at the 16-week time point compared to baseline will be investigated using a paired t-test at a one-sided alpha and a 95% confidence interval for mean change. | 16 weeks | |
Secondary | Change in hair thickness | Increases and/or decreases in hair diameter at the 24-week time point compared to baseline will be investigated using a paired t-test at a one-sided alpha and a 95% confidence interval for mean change. | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02591355 -
Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment
|
N/A | |
Withdrawn |
NCT03852992 -
Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia
|
Phase 2 | |
Recruiting |
NCT06239207 -
Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia
|
Phase 2 | |
Completed |
NCT04945226 -
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
|
Phase 1/Phase 2 | |
Completed |
NCT01548066 -
The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss
|
Phase 2 | |
Completed |
NCT01437163 -
Treatment of Androgenetic Alopecia in Males and Females
|
N/A | |
Completed |
NCT01226459 -
Clinical Trial in Females for Female Pattern Hair Loss
|
Phase 3 | |
Recruiting |
NCT06118866 -
A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia
|
Phase 2 | |
Completed |
NCT06149221 -
Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss
|
N/A | |
Withdrawn |
NCT04882969 -
Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia
|
N/A | |
Completed |
NCT01231607 -
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
|
Phase 3 | |
Completed |
NCT04446429 -
Anti-Androgen Treatment for COVID-19
|
N/A | |
Completed |
NCT02729415 -
Point-of-Care Adipose-derived Cells for Hair Growth
|
N/A | |
Completed |
NCT02279823 -
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
|
Phase 2 | |
Not yet recruiting |
NCT01227031 -
Pharmacogenomic Study of Androgenetic Alopecia
|
N/A | |
Completed |
NCT00981461 -
Treatment of Androgenetic Alopecia in Females, 9 Beam
|
N/A | |
Completed |
NCT01451021 -
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss
|
Phase 2 | |
Completed |
NCT00151515 -
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
|
Phase 3 | |
Completed |
NCT03694067 -
Androgenetic Alopecia and the JAK-STAT Pathway
|
||
Completed |
NCT03689452 -
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
|
N/A |